Immunic (IMUX)
(Delayed Data from NSDQ)
$1.23 USD
-0.01 (-0.81%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $1.24 +0.01 (0.81%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Immunic, Inc. [IMUX]
Reports for Purchase
Showing records 161 - 180 ( 213 total )
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life SciencesThis report contains brief updates on the following: BMRN, VYGR, AQST, AXLA, ICPT, IMUX, VRNA, BPMC, MGNX. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
P2 EMPhASIZES IMU-838?s Best-in-Class Profile; Next, ACTRIMS, P2/COVID-19 in Q3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-838 Shines - and MS Is Only the Beginning. Resuming Buy, $64 PT.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Positive IMU-838 EMPhASIS Phase 2 Multiple Sclerosis Data; Raising PT to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IONIC Trial Initiates Patient Dosing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-838+Tamiflu? Combo/COVID-19 Ph 2 Trial Initiated; Next, RRMS Data in August
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Preview of Next Key Catalyst: IMU-838/RRMS Phase 2 Results in August
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Patients Dosed in CALVID-1 Ph2; Burn Offset by $25 MM from Equity
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
CALVID-1 Trial Patient Dosing Initiated; Cash Replenished; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
CALVID-1 Trial FDA Authorization Received; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Immunic Gets FDA Nod to Start IMU-838/COVID-19 Phase 2 Trial
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L